Salt Lake City-based specialty medical device distributor is poised for value-creating diversification and supply chain innovation.
With more than two decades of healthcare expertise, Hastings brings track record of leading transformative growth.
ARUP Laboratories recently announced an investment in Techcyte Inc. as part of the Orem, Utah-based company’s new $21 million funding round.
On Tuesday, the House Democrats passed a budget blueprint on a party line vote. That blueprint allows Committees in the House to start writing the administration’s $3.5 trillion social spending or “care infrastructure” legislation. Democrats hope to move the spending measure as a reconciliation measure in the Fall. Under the reconciliation process, only 51 votes […]
Nominations are now open for BioUtah’s 2021 awards. The deadline for nominations is September 18.
Known Medicine today announced the closure of its seed round of funding in the amount of $7.2 million led by Caffeinated Capital, with participation from Khosla Ventures, Cota Capital, Kickstart, Forward VC, OATV, Y Combinator and noted angel investors Chris Gibson, CEO & Co-Founder at Recursion Pharmaceuticals, Nish Bhat, previously Co-Founder at Color Genomics, and others.
Fluidx Medical’s GPX™ Embolic Device Use for Tumor Treatments Chosen for “BEST of GEST” Embolization Program at the Annual GEST Meeting.
ZIEN Medical Technologies, of Salt Lake City, Utah, announces the integration of Eclipse Design Innovations, of Woods Cross, Utah, as well as the Grand Opening of their new 16,000 sq foot manufacturing/R&D facility to continue to support the Utah Life Sciences industry.
Renalytix Plc announced the publication of results from an external chronic kidney disease budget impact analysis projecting 5-year savings of $1.1 billion dollars for a population of 100,000 patients with type 2 diabetes (T2DKD) and chronic kidney disease tested with the Renalytix KidneyIntelX™ testing solution. Savings were driven by more effective pharmacy management and appropriate specialist referral compared to current standard of care for patients at high risk for disease progression and kidney failure.
PolarityTE, Inc. today provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) for SkinTE® with a proposed indication for chronic cutaneous ulcers, which was filed on July 23, 2021.
The Biotechnology Innovation Organization (BIO) believes that legislation and public health policies to address this pandemic and the use of FDA authorized and approved COVID-19 vaccines should reflect the best available scientific evidence in order to improve access to and uptake of COVID-19 vaccination. In the U.S., vaccination requirements for school entry, daycare entry, and […]
The Utah Governor’s Office of Economic Opportunity (Go Utah) is pleased to announce that Perfect Day, Inc. is formally expanding its “biology-as-a-service” arm, Scalable Bio Foundry, Inc. (SBF, Inc.) in Utah, bringing up to 64 new high-paying jobs to the state in the next five years.
Javara and Ogden Clinic are proud to announce the launch of a partnership to integrate industry-sponsored clinical trials at the point of care for Ogden Clinic patients.
Tailwind Business Accelerator is giving $50,000 in cash and services to at least 5 companies in its first cohort, starting November 1. Applications close September 17 for this first cohort.
In a recent article published by Utah Business Magazine, Dr. Lincoln Nadauld, Chief of Precision Health at Intermountain Healthcare, provides an explanation of the genomic world and how precision medicine will be evolving in the future. Intermountain Precision Genomics, a BioUtah member, is located in St. George, Utah and is a world leader in genomics.
Recursion, a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, today reported financial results and business updates for its second quarter ending June 30, 2021.
CenExel announces the acquisition of Advanced Memory Research Institute (“CenExel AMRI”), the largest Alzheimer’s Disease clinical research site in the Northeast. CenExel AMRI conducts Phase I through Phase IV studies, primarily in Alzheimer’s Disease, Memory Loss, and Dementia research.
U.S. Ski & Snowboard joins the growing list of professional sports organizations, including NBA and NFL teams, using R-Zero’s tech to reduce health risks from COVID-19 and other airborne and surface pathogens
BioHive on Wednesday was front and center as U.S. Representative Blake Moore (R-UT-1) toured Edwards Lifesciences, BD and Stryker – all leading medical device manufacturers in Utah that provide thousands of good-paying, stable jobs. During the visits, Moore was able to see first-hand the work that these companies do to innovate and produce life-changing technologies. “We […]
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the second quarter ended June 30, 2021.
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the second quarter ended June 30, 2021.
Global life sciences leader Cytiva has acquired Intermountain Life Sciences, a manufacturer of high-purity water, buffers, and liquid cell culture media. Cytiva will use Intermountain’s manufacturing site in Utah to rapidly boost its liquid cell culture production by millions of liters. Hiring is ongoing to rapidly increase output.
ReddyPort, a medical technology company focused on bringing new non-invasive ventilation (NIV) products into market
ELITechGroup is pleased to announce the CE mark for use of saliva on SARS-CoV-2 ELITe MGB® Kit.
The second calendar quarter (2Q) of 2021 financial results were dramatically different from 2Q 2020 because 2Q 2020 results were the low point of Utah Medical Products, Inc.’s (Nasdaq: UTMD) performance during the COVID-19 pandemic, during a time when there were restrictions on so-called nonessential medical procedures. Therefore, UTMD management reports quarterly income statement results compared to the same periods not only in 2021 compared to 2020, but also compared to 2019. The Company’s stated objective in 2021 has been to try to fully recover back to its 2019 financial performance. Please see the income statements for all three years on the last page.
CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of ForCare Clinical Research (“CenExel FCR”), a Tampa-based clinical research organization with Principal Investigators who have more than 40 years of combined research experience. CenExel FCR conducts Phase I through Phase IV studies in both chronic and acute conditions, primarily in Dermatology
Biomerics LLC, a leading mid-market contract manufacturer for the interventional medical device market, announced it has acquired a majority interest in Berg Manufacturing Inc. Berg Manufacturing, based in Santa Clara, California, is an industry leader in Swiss micromachining for the advanced robotic surgery, endoscope, and interventional catheter markets.
Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today launched a new version of its market-leading MyRisk Hereditary Cancer Test. For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the market’s most accurate hereditary cancer test.
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2021 and provided an update on recent business performance and strategic transformation plans.
PolarityTE on July 28 announced final data from a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers (DFU) with its investigational product SkinTE®. The trial met the primary endpoint of wound closure at 12 weeks and secondary endpoint of Percent Area Reduction (PAR) assessed at 4, 6, 8, 10, and 12 weeks. Nikolai […]
PolarityTE recently announced that the China National Intellectual Property Administration (CNIPA) issued a Notification of Allowance for Chinese Patent Application No. 201580075326.3. The allowed claims relate to skin-regenerative compositions utilizing PolarityTE’s minimally polarized functional unit (MPFU) technology as well as methods of making a skin-regenerative composition utilizing the MPFU technology. This most recent allowance further […]
PolarityTE on Monday announced the submission of an investigational new drug application (IND) to the FDA seeking authorization to commence a clinical trial to evaluate its SkinTE product for the proposed indication of treatment of chronic cutaneous ulcers. SkinTE is PolarityTE’s human cellular and tissue-based product derived from a patient’s own skin. David Seaburg, Chief Executive […]
